BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

567 related articles for article (PubMed ID: 28134791)

  • 1. A Tale of Two Signals: AR and WNT in Development and Tumorigenesis of Prostate and Mammary Gland.
    Pakula H; Xiang D; Li Z
    Cancers (Basel); 2017 Jan; 9(2):. PubMed ID: 28134791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interplay Between SOX9, Wnt/β-Catenin and Androgen Receptor Signaling in Castration-Resistant Prostate Cancer.
    Khurana N; Sikka SC
    Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31027362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy.
    Rajan P; Sudbery IM; Villasevil ME; Mui E; Fleming J; Davis M; Ahmad I; Edwards J; Sansom OJ; Sims D; Ponting CP; Heger A; McMenemin RM; Pedley ID; Leung HY
    Eur Urol; 2014 Jul; 66(1):32-9. PubMed ID: 24054872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crosstalk Between AR and Wnt Signaling Promotes Castration-Resistant Prostate Cancer Growth.
    Luo J; Wang D; Wan X; Xu Y; Lu Y; Kong Z; Li D; Gu W; Wang C; Li Y; Ji C; Gu S; Xu Y
    Onco Targets Ther; 2020; 13():9257-9267. PubMed ID: 32982312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA Regulation of Androgen Receptor in Castration-Resistant Prostate Cancer: Premises, Promises, and Potentials.
    Ebrahimi S; Hashemy SI; Sahebkar A; Aghaee Bakhtiari SH
    Curr Mol Pharmacol; 2021 Oct; 14(4):559-569. PubMed ID: 33357209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
    Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
    Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wnt signaling in castration-resistant prostate cancer: implications for therapy.
    Yokoyama NN; Shao S; Hoang BH; Mercola D; Zi X
    Am J Clin Exp Urol; 2014 Apr; 2(1):27-44. PubMed ID: 25143959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the androgen receptor signaling pathway in advanced prostate cancer.
    Chung C; Abboud K
    Am J Health Syst Pharm; 2022 Jul; 79(15):1224-1235. PubMed ID: 35390118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wnt/Beta-Catenin Signaling and Prostate Cancer Therapy Resistance.
    Yeh Y; Guo Q; Connelly Z; Cheng S; Yang S; Prieto-Dominguez N; Yu X
    Adv Exp Med Biol; 2019; 1210():351-378. PubMed ID: 31900917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The androgen receptor can signal through Wnt/beta-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens.
    Schweizer L; Rizzo CA; Spires TE; Platero JS; Wu Q; Lin TA; Gottardis MM; Attar RM
    BMC Cell Biol; 2008 Jan; 9():4. PubMed ID: 18218096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TCF7 is suppressed by the androgen receptor via microRNA-1-mediated downregulation and is involved in the development of resistance to androgen deprivation in prostate cancer.
    Siu MK; Chen WY; Tsai HY; Chen HY; Yin JJ; Chen CL; Tsai YC; Liu YN
    Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):172-178. PubMed ID: 28220803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multifaceted interaction between the androgen and Wnt signaling pathways and the implication for prostate cancer.
    Terry S; Yang X; Chen MW; Vacherot F; Buttyan R
    J Cell Biochem; 2006 Oct; 99(2):402-10. PubMed ID: 16741972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Restoration of FKBP51 protein promotes the progression of castration resistant prostate cancer.
    Yu J; Sun L; Hao T; Zhang B; Chen X; Li H; Zhang Z; Zhu S; Quan C; Niu Y; Shang Z
    Ann Transl Med; 2019 Dec; 7(23):729. PubMed ID: 32042745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcription of Nrdp1 by the androgen receptor is regulated by nuclear filamin A in prostate cancer.
    Savoy RM; Chen L; Siddiqui S; Melgoza FU; Durbin-Johnson B; Drake C; Jathal MK; Bose S; Steele TM; Mooso BA; D'Abronzo LS; Fry WH; Carraway KL; Mudryj M; Ghosh PM
    Endocr Relat Cancer; 2015 Jun; 22(3):369-86. PubMed ID: 25759396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding Mechanisms of Resistance in Metastatic Castration-resistant Prostate Cancer: The Role of the Androgen Receptor.
    Tilki D; Schaeffer EM; Evans CP
    Eur Urol Focus; 2016 Dec; 2(5):499-505. PubMed ID: 28723515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interactions between androgen receptor signaling and other molecular pathways in prostate cancer progression: Current and future clinical implications.
    Pisano C; Tucci M; Di Stefano RF; Turco F; Scagliotti GV; Di Maio M; Buttigliero C
    Crit Rev Oncol Hematol; 2021 Jan; 157():103185. PubMed ID: 33341506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of resistance in castration-resistant prostate cancer (CRPC).
    Chandrasekar T; Yang JC; Gao AC; Evans CP
    Transl Androl Urol; 2015 Jun; 4(3):365-80. PubMed ID: 26814148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
    Karantanos T; Evans CP; Tombal B; Thompson TC; Montironi R; Isaacs WB
    Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.